Overview
The insurer capital top-up wave continues, with about 20 insurers recapitalizing this year. China Merchants Renhe Life received a six-year-later capital injection from its parent; HSBC Life topped up twice (556m done, 472m planned); Shanghai Lujiazui Guotai Life’s two shareholders plan 1bn yuan each, lifting capital from 3bn to 5bn; Guobao Life plans ~2.54bn. Perpetual bonds have become the main capital tool. In September, the Ministry of Finance issued 300bn yuan of special bonds to replenish Tier-1 capital of 8 central financial firms, first including 5 insurance SOEs (70bn total).
Background & Interpretation
1. Regulatory and Industry Context
Under C-ROSS Phase II, only future earnings from policies with over 10-year residual maturity count toward core capital (cap 35%), pressuring many insurers’ core capital. Low rates squeeze investment returns and asset-liability matching, while business growth and equity allocations consume solvency capital, making external replenishment necessary.
2. Drivers and Mechanism
Two channels: capital-instrument innovation—perpetual bonds supplement other Tier-1 capital without diluting control, becoming mainstream; and shareholder/sovereign capital, with special bonds first covering insurance SOEs as prudent, forward-looking support. China Bond Rating notes core-capital declines mainly from tighter Phase II surplus recognition.
3. Market Structure and Implications
Large insurers are adequately capitalized and top up preemptively; smaller ones rely more on issuance to maintain solvency. Thicker capital opens long-term equity allocation space, providing mid-/long-term market support. Ratings and underwriting houses gain business.
Implications & Outlook
Near term, perpetual bonds and capital increases remain密集, stabilizing solvency metrics. Longer term, over-reliance on external funding raises leverage and liquidity pressure; boosting endogenous capital via business-structure optimization is fundamental. Watch special-bond pace, perpetual-bond yields and Phase II tweaks.
Takeaways for Industry Participants
Insurer management should balance external top-ups with endogenous accumulation and improve ALM. Investors should weigh solvency and capital-instrument defensive value. Regulators should time injections between risk control and development.